Blaine Labs Issues Voluntary Nationwide Recall of Wound Care Gel Products Due to Microbial Contamination
Blaine Labs, Inc., a healthcare products manufacturer based in Santa Fe Springs, California, has announced a voluntary nationwide recall of specific lots of its wound care gel products. The recall affects three lot numbers of Revitaderm® and Tridergel™ wound care gels in both 1 oz. and 3 oz. packaging formats. These products contain 0.1% benzalkonium chloride and are commonly used as topical antiseptics for minor cuts, scrapes, and burns.
The company initiated the recall after discovering microbial contamination in certain product samples. Although no adverse events have been reported to date, the recall has been undertaken as a precautionary measure to protect patient safety and prevent potential health risks.
Reason for the Recall: Microbial Contamination
The recall was triggered following the detection of Lysinibacillus fusiformis in tested samples. This organism is an environmental, spore-forming bacterium that can survive in harsh conditions. While it is generally considered to have low pathogenicity in healthy individuals, its presence in a medical or wound care product raises concerns.
Microbial contamination in topical products can compromise their safety and effectiveness. In this case, the contamination could potentially lead to infection or delayed healing when applied to open wounds or damaged skin.
Understanding the Potential Health Risks
Although Lysinibacillus fusiformis is not typically harmful to healthy individuals, it may act as an opportunistic pathogen in certain populations. The risk is particularly higher for individuals with:
- Open wounds or compromised skin barriers
- Weakened immune systems
- Chronic conditions such as diabetes
- Advanced age (elderly individuals)
- Immature immune systems (young children)
In these vulnerable groups, exposure to contaminated products may lead to complications such as:
- Skin irritation or localized infection
- Delayed wound healing
- More severe infections in rare cases
In extreme scenarios, especially among immunocompromised individuals, infections could escalate into life-threatening conditions such as endocarditis (infection of the heart lining) or central nervous system infections.
Description of the Affected Products
The recalled products are topical antiseptic gels intended for first aid use. They help reduce the risk of infection in minor injuries such as cuts, scrapes, and burns.
The affected products include:
Revitaderm® Wound Care Antiseptic Gel
- Available in 1 oz. bottles and 3 oz. tubes
- Identified by purple trim packaging
- Active ingredient: Benzalkonium Chloride 0.1%
Tridergel™ Wound Care
- Available in 1 oz. bottles
- Identified by light blue trim packaging
- Active ingredient: Benzalkonium Chloride 0.1%
Packaging details vary slightly:
- 1 oz. bottles may have either a twist cap or a longer pointed cap
- Bottles are sealed with a shrink/body band
- Lot numbers and expiration dates are printed on the bottom of bottles
- 3 oz. tubes have lot numbers and expiration dates imprinted on the crimp at the top
Affected Lot Numbers and Expiration Dates
The recall specifically applies to the following lot numbers:
Revitaderm® Wound Care Antiseptic Gel
- Lot BL3608 – Expiration: 07/01/2028 (1 oz., twist cap)
- Lot BL3435 – Expiration: 11/06/2026 (1 oz. and 3 oz.)
- Lot BL3525 – Expiration: 08/07/2027 (1 oz. and 3 oz.)
Tridergel™ Wound Care
- Lot BL3435 – Expiration: 11/06/2026 (1 oz.)
Healthcare providers and users are advised to carefully check product packaging for these lot numbers and expiration dates.
Distribution and Availability
The affected products were distributed nationwide across the United States. However, it is important to note that these items were not sold through retail stores or online platforms. Instead, they were supplied directly to healthcare providers, including physician offices.
This means the primary users of these products are healthcare professionals and patients receiving treatment in clinical settings.
No Reported Adverse Events
As of the time of the recall announcement, Blaine Labs has not received any reports of adverse reactions or health issues related to the affected products. Despite this, the company has chosen to act proactively by removing potentially compromised products from circulation.
This approach reflects a commitment to patient safety and adherence to quality standards in healthcare manufacturing.
Instructions for Customers and Healthcare Providers
Blaine Labs has issued clear guidance for healthcare providers and customers who may have the affected products:
- Immediately stop using the product
Discontinue use of any products belonging to the affected lot numbers. - Check inventory
Carefully review all stock to identify recalled items. - Segregate affected products
Separate the recalled products from other inventory to prevent accidental use or distribution. - Arrange for return
Contact Blaine Labs, Inc. to coordinate the return of affected products.
The company is directly notifying physician clinics via mail and phone and is facilitating the return of unused inventory.
Reporting Adverse Events
Patients or healthcare providers who experience any adverse reactions or quality issues related to these products are encouraged to report them promptly.
Reports can be submitted to the U.S. Food and Drug Administration through its MedWatch Adverse Event Reporting program using the following methods:
- Online submission via the MedWatch website
- Mail or fax using downloadable reporting forms
- Phone request for reporting forms
This reporting system helps regulatory authorities monitor product safety and take appropriate action when needed.
Company Response and Regulatory Oversight
Blaine Labs is conducting this recall with the knowledge of the FDA, ensuring compliance with regulatory standards. The company is also providing support to affected customers through direct communication channels, including phone and email assistance during business hours.
By initiating a voluntary recall, Blaine Labs demonstrates its commitment to transparency, quality control, and patient safety. Such actions are essential in maintaining trust within the healthcare community and ensuring that potentially harmful products are promptly removed from use.
Importance of Vigilance in Healthcare Products
This recall highlights the importance of strict quality control and monitoring in the manufacturing of healthcare products. Even products intended for minor injuries can pose significant risks if contamination occurs.
Healthcare providers and consumers alike are encouraged to remain vigilant by:
- Regularly checking product lot numbers and expiration dates
- Following recall announcements
- Reporting any unusual product behavior or health effects
About
The voluntary recall of Blaine Labs’ wound care gels underscores the company’s proactive approach to addressing potential safety concerns. While the risk to healthy individuals may be low, the presence of microbial contamination—especially in products used on open wounds—necessitates immediate action.
By promptly identifying affected products, notifying healthcare providers, and coordinating returns, Blaine Labs aims to minimize any potential health risks and maintain high standards of patient care.
Customers and healthcare professionals are urged to follow recall instructions carefully and report any concerns to ensure continued safety and accountability in the use of medical products.
